Vanda Pharmaceuticals (VNDA) Total Liabilities (2009 - 2026)

Vanda Pharmaceuticals has disclosed Total Liabilities across 18 years of filings, most recently posting $152.8 million for Q1 2026.

• Total Liabilities for Q1 2026 came in at $152.8 million, up 26.75% year-over-year; the trailing twelve-month figure through Mar 2026 was $152.8 million (up 26.75% YoY), and the FY2025 annual result was $161.8 million, up 37.48% from the prior year.
• Total Liabilities came in at $152.8 million for Q1 2026 at Vanda Pharmaceuticals, down from $161.8 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $161.8 million in Q4 2025 to a low of $98.5 million in Q3 2023.
• The 5-year median for Total Liabilities is $108.7 million (2024), against an average of $116.2 million.
• Across the five-year window, Total Liabilities retreated 7.19% in 2023 and surged 37.48% in 2025, its largest moves.
• Vanda Pharmaceuticals' Total Liabilities stood at $107.0 million in 2022, then declined by 3.29% to $103.5 million in 2023, then advanced by 13.65% to $117.7 million in 2024, then jumped by 37.48% to $161.8 million in 2025, then retreated by 5.56% to $152.8 million in 2026.
• The last three Total Liabilities figures came in at $152.8 million (Q1 2026), $161.8 million (Q4 2025), and $135.1 million (Q3 2025), per Business Quant data.